PPI meds cause hypomagnesaemia and thus may cause stroke and CVD

[[e-mail] |]

If you notice the first point is now included in the television
adverts for these drugs.

Also PPI meds to the treatment of most chronic heartburn/chronic
reflux is a deeply flawed treatment that will worsen and sicken
the patients/medical victims over the years of use.


1. Am J Clin Nutr. 2012 Feb;95(2):362-6. Epub 2011 Dec 28.

Dietary magnesium intake and risk of stroke: a meta-analysis of
prospective
studies.

Larsson SC, Orsini N, Wolk A.

Division of Nutritional Epidemiology, National Institute of
Environmental
Medicine, Karolinska Institutet, Stockholm, Sweden.

BACKGROUND: Prospective studies of dietary magnesium intake in
relation to risk
of stroke have yielded inconsistent results.
OBJECTIVE: We conducted a dose-response meta-analysis to summarize the
evidence
regarding the association between magnesium intake and stroke risk.
DESIGN: Relevant studies were identified by searching PubMed and
EMBASE from
January 1966 through September 2011 and reviewing reference lists of
retrieved
articles. We included prospective studies that reported RRs with 95%
CIs of
stroke for ≥3 categories of magnesium intake. Results from individual
studies
were combined by using a random-effects model.
RESULTS: Seven prospective studies, with 6477 cases of stroke and
241,378
participants, were eligible for inclusion in the meta-analysis. We
observed a
modest but statistically significant inverse association between
magnesium intake
and risk of stroke. An intake increment of 100 mg Mg/d was associated
with an 8%
reduction in risk of total stroke (combined RR: 0.92; 95% CI: 0.88,
0.97),
without heterogeneity among studies (P = 0.66, I(2) = 0%). Magnesium
intake was
inversely associated with risk of ischemic stroke (RR: 0.91; 95% CI:
0.87, 0.96)
but not intracerebral hemorrhage (RR: 0.96; 95% CI: 0.84, 1.10) or
subarachnoid
hemorrhage (RR: 1.01; 95% CI: 0.90, 1.14).
CONCLUSION: Dietary magnesium intake is inversely associated with risk
of stroke,
specifically ischemic stroke.

PMID: 22205313 [PubMed - in process]

1. Neth J Med. 2009 May;67(5):169-72.

Hypomagnesaemia due to use of proton pump inhibitors--a review.

Kuipers MT, Thang HD, Arntzenius AB.

Department of Internal Medicine, Spaarne Hospital, Hoofddorp, the
Netherlands.

Magnesium homeostasis is essential for many intracellular processes
and depends
on the balance of intestinal absorption and renal excretion.
Hypomagnesaemia may
arise from various disorders. We review the literature on
hypomagnesaemia due to
the use of proton pump inhibitors, as illustrated by a case of a 76-
year-old
woman with muscle cramps and lethargy caused by hypomagnesaemia and
hypocalcaemia
with a low parathyroid hormone level while using esomeprazole, a
proton pump
inhibitor (PPI). After oral magnesium repletion both abnormalities
resolved.
Fractional magnesium excretion was low, excluding excessive renal
loss. A causal
relation with PPI use was supported by the recurrence of
hypomagnesaemia after
rechallenge. In the past decade our understanding of transcellular
magnesium
transport was enhanced by the discovery of several gene mutations i.e.
transient
receptor potential melastin (TR PM) 6 and 7. In this light we discuss
the
possible aetiology of proton pump inhibitor related hypomagnesaemia.

PMID: 19581665 [PubMed - indexed for MEDLINE]

Full article available from link at PubMed at no charge.

[[e-mail] |]

1. Ned Tijdschr Geneeskd. 2009;153:A711.

[An unknown but potentially serious side effect of proton pump
inhibitors:
hypomagnesaemia].

[Article in Dutch]

Doornebal J, Bijlsma R, Brouwer RM.


And these meds lower others levels as well in adverse ways.
Proof that your local MD and Med provideres are QUACKs.



Medisch Spectrum Twente, afd. Interne Geneeskunde, Enschede,
The Netherlands.
***@mst.nl

Long-term use of proton pump inhibitors can lead to serious
hypomagnesaemia.
Intestinal magnesium absorption takes place by passive paracellular
and active
transcellular transport. It has been hypothesized that proton pump
inhibitors
impair the active transcellular magnesium transport. The resulting
hypomagnesaemia may cause hypoparathyroidism, hypocalcaemia and
hypokalaemia.
Proton pump inhibitor-induced hypomagnesaemia is reversible: it
resolves when
proton pump inhibitors are stopped. The indication for long-term
proton pump
inhibitor treatment should be evaluated periodically.

PMID: 19930736 [PubMed - indexed for MEDLINE]

[[e-mail] |]

So much for "science based" medicine, here it is admitted
they don't understand the mechanism for this adverse effect.
But it is a drug class effect so it doesn't apparently matter
which PPI med the MD chooses to use on you/victim/patient.


1. Curr Opin Gastroenterol. 2011 Mar;27(2):180-5.

Proton pump inhibitors and severe hypomagnesaemia.

Cundy T, Mackay J.

Department of Medicine,
Faculty of Medical and Health Sciences,
University of Auckland,
Auckland, New Zealand. ***@auckland.ac.nz

PURPOSE OF REVIEW:
Hypomagnesaemia has recently been recognized as a rare, but
severe, complication of proton pump inhibitor (PPI) use. We reviewed
all the
cases published to date in peer-reviewed journals to summarize what is
known of
the epidemiology, risk factors, cause and treatment.

RECENT FINDINGS:
Hypomagnesaemia has been described with all substituted
pyridylmethylsulphonyl benzimidazadole derivatives and is a class
effect,
recurring with substitution of one PPI for another. A long duration of
use and
high rates of adherence are probably risk factors, but the prevalence
is unknown.
The diagnosis is often missed, despite the severe symptomatology.
Renal magnesium
handling is normal, so implicating impairment of net intestinal
absorption as the
proximate cause. It is not known whether this is the consequence of
defective
absorption of magnesium through the active or passive transport
processes, or
increased losses.
SUMMARY:
PPI-associated hypomagnesaemia is a rare, but potentially
life-threatening, side-effect that has emerged only in the era of mass
use of
these agents. The cause of hypomagnesaemia remains poorly understood,
but it
responds rapidly to withdrawal of the PPI.

PMID: 20856115 [PubMed - indexed for MEDLINE]